Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 1073-1080

  Schuhmacher, Anna ^a   Becker, Tim ^a,b   Rujescu, Dan ^c   Quednow, Boris B ^a,d   Lennertz, Leonhard ^a   Wagner, Michael ^a   Benninghoff, Jens ^c,e   Rietschel, Marcella ^f   Häfner, Heinz ^f   Franke, Petra ^g   Wölwer, Wolfgang ^g   Gaebel, Wolfgang ^g   Maier, Wolfgang ^a   Mössner, Rainald ^a  

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g Department of Orthopedic Surgery   (Germany)

Author keywords

Association study; Cognition; PPI; Response antipsychotics; Schizophrenia; TPH2

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRYPTOPHAN HYDROXYLASE 2; ZIPRASIDONE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RATING SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; GAIT DISORDERS, NEUROLOGIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRYPTOPHAN HYDROXYLASE; YOUNG ADULT;

EID: 84863430321     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.021     Document Type: Article

References (60)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. The Journal of Neuropsychiatry & Clinical Neurosciences 1997, 9(1):1-17.
2. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955, 11(3):375-386.
3. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry 2007, 12(8):707-747.
4. Arranz M.J., Collier D.A., Munro J., Sham P., Kirov G., Sodhi M., et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuroscience Letters 1996, 217(2-3):177-178.
5. Baehne C.G., Ehlis A.C., Plichta M.M., Conzelmann A., Pauli P., Jacob C., et al. Tph2 gene variants modulate response control processes in adult ADHD patients and healthy individuals. Molecular Psychiatry 2009, 14(11):1032-1039.
6. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
7. Becker T., Herold C. Joint analysis of tightly linked SNPs in screening step of genome-wide association studies leads to increased power. European Journal of Human Genetics 2009, 17(8):1043-1049.
8. Benton A.L., Hamsher K. Multilingual aphasia examination 1989, AJA Associates, Iowa City Iowa.
9. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Research 1988, 26(2):223-238.
10. De Luca V., Likhodi O., Van Tol H.H., Kennedy J.L., Wong A.H. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berl) 2005, 183(3):378-382.
11. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry 2007, 64(5):532-542.
12. Gaebel W., Moller H.J., Buchkremer G., Ohmann C., Riesbeck M., Wolwer W., et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2004, 254(2):129-140.
13. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. The American Journal of Psychiatry 2003, 160(4):636-645.
14. Helmstaedter C., Lendt M., Lux S. Verbaler Lern- und Merkfähigkeitstest 2001, Beltz, Göttingen.
15. Herold C., Becker T. Genetic association analysis with FAMHAP: a major program update. Bioinformatics 2009, 25(1):134-136.
16. Higashi S., Ohnuma T., Shibata N., Higashi M., Matsubara Y., Arai H. No genetic association between tryptophan hydroxylase 2 gene polymorphisms and Japanese schizophrenia. Psychiatric Genetics 2007, 17(2):123.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
18. Kishi T., Tsunoka T., Ikeda M., Kitajima T., Kawashima K., Okochi T., et al. Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology 2009.
19. Li D., He L. Meta-analysis shows association between the tryptophan hydroxylase (TPH) gene and schizophrenia. Human Genetics 2006, 120(1):22-30.
20. Lin Y.M., Chao S.C., Chen T.M., Lai T.J., Chen J.S., Sun H.S. Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Archives of General Psychiatry 2007, 64(9):1015-1024.
21. Marziniak M., Kienzler C., Kuhlenbaumer G., Sommer C., Mossner R. Functional gene variants of the serotonin-synthesizing enzyme tryptophan hydroxylase 2 in migraine. Journal of Neural Transmission 2009, 116(7):815-819.
22. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003, 27(7):1159-1172.
23. Möller H.J., Riedel M., Jager M., Wickelmaier F., Maier W., Kuhn K.U., et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. The International Journal of Neuropsychopharmacology 2008, 11(7):985-997.
24. Mössner R., Freitag C.M., Gutknecht L., Reif A., Tauber R., Franke P., et al. The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. Journal of Psychopharmacology 2006, 20(4):547-552.
25. Mössner R., Walitza S., Geller F., Scherag A., Gutknecht L., Jacob C., et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. The International Journal of Neuropsychopharmacology 2006, 9(4):437-442.
26. Mössner R., Muller-Vahl K.R., Doring N., Stuhrmann M. Role of the novel tryptophan hydroxylase-2 gene in Tourette syndrome. Molecular Psychiatry 2007, 12(7):617-619.
27. Mössner R., Schuhmacher A., Schulze-Rauschenbach S., Kuhn K.U., Rujescu D., Rietschel M., et al. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. European Neuropsychopharmacology 2008, 18(10):768-772.
28. Mössner R., Schuhmacher A., Kuhn K.U., Cvetanovska G., Rujescu D., Zill P., et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics 2009, 19(1):91-94.
29. Osinsky R., Schmitz A., Alexander N., Kuepper Y., Kozyra E., Hennig J. TPH2 gene variation and conflict processing in a cognitive and an emotional Stroop task. Behavioural Brain Research 2009, 198(2):404-410.
30. Patel P.D., Pontrello C., Burke S. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biological Psychiatry 2004, 55(4):428-433.
31. Purcell S., Cherny S.S., Sham P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19(1):149-150.
32. Quednow B.B., Kuhn K.U., Beckmann K., Westheide J., Maier W., Wagner M. Attenuation of the prepulse inhibition of the acoustic startle response within and between sessions. Biological Psychology 2006, 71(3):256-263.
33. Quednow B.B., Frommann I., Berning J., Kuhn K.U., Maier W., Wagner M. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biological Psychiatry 2008, 64(9):766-773.
34. Quednow B.B., Kuhn K.U., Mossner R., Schwab S.G., Schuhmacher A., Maier W., et al. Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biological Psychiatry 2008, 64(5):434-437.
35. Quednow B.B., Schmechtig A., Ettinger U., Petrovsky N., Collier D.A., Vollenweider F.X., et al. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry 2009, 66(6):614-620.
36. Quednow B.B., Wagner M., Mossner R., Maier W., Kuhn K.U. Sensorimotor gating of schizophrenia patients depends on catechol O-methyltransferase Val158Met polymorphism. Schizophrenia Bulletin 2010, 36(2):341-346.
37. Quednow B.B., Ettinger U., Mossner R., Rujescu D., Giegling I., Collier D.A., et al. The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. The Journal of Neuroscience 2011, 31(18):6684-6691.
38. Reitan R.M., Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation 1993, Neuropsychology Press, Tucson, Arizona. 2nd ed.
39. Reuter M., Ott U., Vaitl D., Hennig J. Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene. Journal of Cognitive Neuroscience 2007, 19(3):401-408.
40. Reuter M., Esslinger C., Montag C., Lis S., Gallhofer B., Kirsch P. A functional variant of the tryptophan hydroxylase 2 gene impacts working memory: a genetic imaging study. Biological Psychology 2008, 79(1):111-117.
41. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. The American Journal of Psychiatry 2006, 163(10):1826-1829.
42. Saetre P., Lundmark P., Hansen T., Rasmussen H.B., Djurovic S., Melle I., et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009.
43. Serretti A., Chiesa A., Porcelli S., Han C., Patkar A.A., Lee S.J., et al. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research 2011, 189(1):26-32.
44. Shiroiwa K., Hishimoto A., Mouri K., Fukutake M., Supriyanto I., Nishiguchi N., et al. Common genetic variations in TPH1/TPH2 genes are not associated with schizophrenia in Japanese population. Neuroscience Letters 2011, 472(3):194-198.
45. Steffens M., Becker T., Sander T., Fimmers R., Herold C., Holler D.A., et al. Feasible and successful: genome-wide interaction analysis involving all 1.9 × 10(11) pair-wise interaction tests. Human Heredity 2010, 69(4):268-284.
46. Strobel A., Dreisbach G., Muller J., Goschke T., Brocke B., Lesch K.P. Genetic variation of serotonin function and cognitive control. Journal of Cognitive Neuroscience 2007, 19(12):1923-1931.
47. Swan G.E., Carmelli D. Evidence for genetic mediation of executive control: a study of aging male twins. The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences 2002, 57(2):P133-P143.
48. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. The Journal of Clinical Psychiatry 2011, 72(Suppl.):14-18.
49. Tee S.F., Chow T.J., Tang P.Y., Loh H.C. Linkage of schizophrenia with TPH2 and 5-HTR2A gene polymorphisms in the Malay population. Genetics and Molecular Research 2010, 9(3):1274-1278.
50. The International HapMap Consortium A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449(7164):851-861.
51. Walther D.J., Bader M. A unique central tryptophan hydroxylase isoform. Biochemical Pharmacology 2003, 66(9):1673-1680.
52. Walther D.J., Peter J.U., Bashammakh S., Hortnagl H., Voits M., Fink H., et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299(5603):76.
53. Wang L., Fang C., Zhang A., Du J., Yu L., Ma J., et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. Journal of Psychopharmacology 2008, 22(8):904-909.
54. Wechsler D. Wechsler adult intelligence scale 1997, Psychological Corp, San Antonio, Texas. 3rd ed.
55. Wölwer W., Buchkremer G., Hafner H., Klosterkotter J., Maier W., Moller H.J., et al. German research network on schizophrenia-bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience 2003, 253(6):321-329.
56. Zaboli G., Jonsson E.G., Gizatullin R., Asberg M., Leopardi R. Tryptophan hydroxylase-1 gene variants associated with schizophrenia. Biological Psychiatry 2006, 60(6):563-569.
57. Zhang C., Li Z., Shao Y., Xie B., Du Y., Fang Y., et al. Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. Journal of Molecular Neuroscience 2011, 43(3):406-411.
58. Zhou Z., Roy A., Lipsky R., Kuchipudi K., Zhu G., Taubman J., et al. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Archives of General Psychiatry 2005, 62(10):1109-1118.
59. Zill P., Buttner A., Eisenmenger W., Moller H.J., Bondy B., Ackenheil M. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biological Psychiatry 2004, 56(8):581-586.
60. Zill P., Buttner A., Eisenmenger W., Muller J., Moller H.J., Bondy B. Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 2009, 159(4):1274-1282.